Shots:
- The DSMB recommended continued the dosing in the P- I/II clinical trial assessing AMT-130 in patients with a second higher-dose cohort, after review safety data from the first cohort of ten patients
- The first cohort of P- I/II trial for AMT-130 in 10 patients out of which six patients received treatment with AMT-130 and four patients received imitation surgery for early manifest HD. UniQure will now begin to enroll patients in the higher-dose cohort of the trial
- The company initiates clinical development of the therapy in Europe in H2’21 and share initial imaging and biomarker data from the US clinical trial in 2021
Click here to read full press release/ article | Ref: Globe Newswire | Image: STAT News
The post uniQure Provides Positive Recommendation to Advance P- I/II Study of AMT-130 for Huntington Disease first appeared on PharmaShots.
